泰素及顺铂联合治疗晚期非小细胞肺癌

Combination of Paclitaxel and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

目的：观察抗肿瘤新药泰素（紫杉醇，Paclitaxel）加顺铂治疗晚期非小细胞肺癌（NSCLC）的疗效及毒性反应。方法：泰素180mg/m3静滴第1天，用泰素前给予抗过敏处理。顺铂25mg/m2静滴第2－4天.每三周重复，每例均完成二周期化疗。结果：14例晚期NSCLC病人中，部分缓解（PR）4例，稳定（NC）7例，进展（PD）3例。总有效率28．6％。初治有效率40％（2／5），复治有效率22％（2／9）。主要副作用是骨髓抑制，神径肌肉毒性也相当常见。结论：以泰素为主的联合方案治疗晚期NSCLC能取得一定疗效，对初治者有较好的缓解率。毒副作用可以耐受。

To evaluate the results of the treatment of advanced non - small cell lung cancer(NSCLC) with the new antitumor drug paclitaxel and cisplatin. Methods: Fourteen patients with advancedNSCLC were treated with paclitaxel (180 mg/m2) on the first day, on the basis of preantianaphylactictreatment and cisplatin (25mg/m2) on the 2- 4th day. Course was repeated every 3 weeks and each casecompleted 2 cycles. Results: Four patients reached partial response. The overall response late was28. 6%. The primary response rate reached 40% (2/5). The subsequent response rate was 22% (2/9).The major toxic effect was myelosuppression. myelosuppression Peripheral neuropathy toxicity and myalgia were also observed. Conclusion: Paclitaxel plus cisplatin was an active regimen in NSCLC. The remission rate in primary patients can be better. The toxicity was tolerable.